Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2551Triple Negative Breast Neoplasms 436Carcinoma, Non-Small-Cell Lung 339Ovarian Neoplasms 315Neoplasms 281Neoplasm Metastasis 253Colorectal Neoplasms 246Stomach Neoplasms 202Pancreatic Neoplasms 196Prostatic Neoplasms 188Lung Neoplasms 180Melanoma 171Squamous Cell Carcinoma of Head and Neck 140Endometrial Neoplasms 140Head and Neck Neoplasms 124Carcinoma, Renal Cell 118Uterine Cervical Neoplasms 104Esophageal Neoplasms 97Urinary Bladder Neoplasms 92Small Cell Lung Carcinoma 87Sarcoma 85Colonic Neoplasms 80Carcinoma, Hepatocellular 62Carcinoma, Transitional Cell 61Kidney Neoplasms 51Advanced Breast Cancer 51Cholangiocarcinoma 50Liver Neoplasms 47Brain Neoplasms 43Mesothelioma 37

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Inoperable Locally Advanced HER2-Negative Breast Cancer × Breast × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡